US Senate passes FDA Revitalization Act.
作者信息
Guthrie Patricia
出版信息
CMAJ. 2007 Jul 3;177(1):23. doi: 10.1503/cmaj.070779.
Abstract
摘要
相似文献
1
US Senate passes FDA Revitalization Act.
CMAJ. 2007 Jul 3;177(1):23. doi: 10.1503/cmaj.070779.
2
Roadmap for revitalization?
Nat Biotechnol. 2007 Oct;25(10):1061. doi: 10.1038/nbt1007-1061.
3
Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
Fed Regist. 2000 Oct 30;65(210):64607-19.
4
Drug safety reform at the FDA--pendulum swing or systematic improvement?
N Engl J Med. 2007 Apr 26;356(17):1700-2. doi: 10.1056/NEJMp078057. Epub 2007 Apr 13.
5
New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
Fed Regist. 1992 Dec 11;57(239):58942-60.
6
Pharmaceuticals and medical devices: FDA oversight. Issue brief.
Issue Brief Health Policy Track Serv. 2012 Dec 31:1-79.
7
Today's FDA.
N Engl J Med. 2005 Jan 20;352(3):293-7. doi: 10.1056/NEJMsb042278.
8
FDA attempting to overcome major roadblocks in monitoring drug safety.
J Natl Cancer Inst. 2005 Jun 15;97(12):872-3. doi: 10.1093/jnci/97.12.872.
9
FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
Gastroenterology. 2008 Apr;134(4):905. doi: 10.1053/j.gastro.2008.02.070.
10
Regulatory considerations for determining postmarketing study commitments.
Clin Pharmacol Ther. 2007 Aug;82(2):228-30. doi: 10.1038/sj.clpt.6100238. Epub 2007 May 30.
引用本文的文献
1
Postmarketing Research and Surveillance: Issues and Challenges.
Monitor (Assoc Clin Pharmacol). 2008 Apr;22(2):45-48.
Zotero 插件